Phaseline

Targets › EPHX2

EPHX2 (Bifunctional epoxide hydrolase 2 [Includes: Cytosolic epoxide hydrolase 2): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 1; Neurology, Genitourinary; next expected readout Dec 2026.

Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. (UniProt, P34913)

Open in Phaseline: the race on EPHX2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EicOsis Human HealthEC5026
Soluble epoxide hydrolase (sEH) inhibitor
EPHX2Phase 1Parkinson's Disease (PD); Chronic Kidney Disease; Spinal Cord InjuriesDec 2026

Conditions

Parkinson's Disease (PD) (1) Chronic Kidney Disease (1) Spinal Cord Injuries (1)

Modalities

small molecule (1)

Companies

EicOsis Human Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.